Results 51 to 60 of about 195,947 (275)
Current and promising novel drug candidates against visceral leishmaniasis
Pure and Applied Chemistry, 2019 Leishmaniasis is a group of zoonotic diseases caused by a trypanosomatid parasite mostly in impoverished populations of low-income countries. In their different forms, leishmaniasis is prevalent in more than 98 countries all over the world and ...
Rosa M. Reguera +7 more
semanticscholar +1 more source
European Journal of Clinical Investigation, EarlyView.Controlled Human Infection Models (CHIMs) offer a powerful approach to accelerate vaccine development for neglected tropical diseases (NTDs). This review highlights scientific and translational advances enabled by CHIMs, with a focus on a novel Leishmania major model.
Vivak Parkash
wiley +1 more source
Journal of Vector Borne Diseases, 2018 Visceral leishmaniasis (VL) is an important parasitic disease which is endemic in different parts of Iran; and domestic and wild canines are principal reservoir hosts of the disease.
M. Mohebali, E. Moradi-Asl, Y. Rassi
semanticscholar +1 more source
The FEBS Journal, EarlyView.The Leishmania phosphatase PTP1, and possibly the genetically similar PTP2, interacts with the Leishmania transmembrane protein DUF21. When both ptp1 and ptp2 are knocked out of Leishmania (LdΔPTP1/2), the parasite can no longer survive without magnesium in vitro and has reduced viability in the host macrophage. Conversely, in duf21 knockout (LdΔDUF21),
Kayla Paulini +6 more
wiley +1 more source
Histological Disorganization of Spleen Compartments and Severe Visceral Leishmaniasis
Frontiers in Cellular and Infection Microbiology, 2018 The spleen is a secondary lymphoid organ responsible for immune surveillance against blood-circulating pathogens. Absence of the spleen is associated with increased susceptibility to systemic spread and fatal infection by different pathogens.
M. D. Hermida +4 more
semanticscholar +1 more source
Treatment of visceral leishmaniasis [PDF]
International Journal of Infectious Diseases, 2001 Growing antimony resistance in patients with visceral leishmaniasis (VL) over last two decades, especially in Indian subcontinent, renders this cheap and easily available drug useless for a vast majority of patients. Use of the second line drug pentamidine isethionate, a toxic drug with declining efficacy, has largely been abandoned.
openaire +2 more sources
Artificial intelligence‐powered microscopy: Transforming the landscape of parasitology
Journal of Microscopy, EarlyView.Abstract Microscopy and image analysis play a vital role in parasitology research; they are critical for identifying parasitic organisms and elucidating their complex life cycles. Despite major advancements in imaging and analysis, several challenges remain. These include the integration of interdisciplinary data; information derived from various model
Mariana De Niz +4 more
wiley +1 more source
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
Therapeutics and Clinical Risk Management, 2012 Viroj Wiwanitkit1–31Wiwanitkit House, Bang Khae, Bangkok, Thailand; 2Hainan Medical University, Haikou, Hainan, People's Republic of China; 3Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, NigeriaAbstract: Leishmaniasis is an
Wiwanitkit V
doaj
Case Reports in Infectious Diseases, 2014 Leishmaniasis is a tropical infection caused by the protozoan, belonging to the group of Leishmania which causes Old World and New World disease. These are typically divided into cutaneous, mucocutaneous, visceral, viscerotropic, and disseminated disease.
Cyriac Abby Philips +4 more
doaj +1 more source
International Journal of Infectious Diseases, 2019 Eighty years after the last published record of human leishmaniasis from Dagestan, Russian Federation, we report two recent cases which were most probably acquired locally: one case of visceral leishmaniasis in a 2-year old child, and one cutaneous ...
Sergey Andreevich Nagorny +6 more
doaj +1 more source